Price Action Report: Zynerba Pharmaceuticals Inc’s Stock Is Sell After Today’s Significant Decline

Price Action Report: Zynerba Pharmaceuticals Inc's Stock Is Sell After Today's Significant Decline

The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! The stock decreased 3.87% or $0.54 on October 5, hitting $13.43. About 253,434 shares traded hands. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 132.83% since March 2, 2016 and is uptrending. It has outperformed by 124.58% the S&P500.
The move comes after 7 months negative chart setup for the $125.99 million company. It was reported on Oct, 5 by We have $11.68 PT which if reached, will make NASDAQ:ZYNE worth $16.38 million less.

Analysts await Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to report earnings on November, 9. They expect $-0.60 earnings per share, down 3.45% or $0.02 from last year’s $-0.58 per share. After $-0.70 actual earnings per share reported by Zynerba Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -14.29% EPS growth.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Ratings Coverage

Out of 4 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zynerba Pharmaceuticals has been the topic of 6 analyst reports since August 31, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating given on Monday, August 31 by Piper Jaffray. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has “Buy” rating given on Monday, August 31 by Jefferies. On Thursday, November 12 the stock rating was maintained by Oppenheimer with “Outperform”. Canaccord Genuity initiated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) on Monday, September 14 with “Buy” rating. The firm earned “Outperform” rating on Tuesday, September 8 by Oppenheimer.

According to Zacks Investment Research, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.”

Another recent and important Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) news was published by which published an article titled: “News Zynerba Pharmaceuticals Inc.ZYNE” on July 31, 2015.

ZYNE Company Profile

Zynerba Pharmaceuticals, Inc., incorporated on January 31, 2007, is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Firm is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment